Persistently Increased Serum Concentration of Heart-Type Fatty Acid-Binding Protein Predicts Adverse Clinical Outcomes in Patients With Chronic Heart Failure

  • Niizeki Takeshi
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Takeishi Yasuchika
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Arimoto Takanori
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Nozaki Naoki
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Hirono Osamu
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Watanabe Tetsu
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Nitobe Joji
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Miyashita Takehiko
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Miyamoto Takuya
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Koyama Yo
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Kitahara Tatsuro
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Suzuki Satoshi
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Sasaki Toshiki
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
  • Kubota Isao
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

Search this article

Abstract

Background Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein that is released into the circulation when the myocardium is injured. This study examined whether serial measurement of the H-FABP level provides additional prognostic information. Methods and Results Serum H-FABP levels were measured in 113 consecutive chronic heart failure (CHF) patients at both admission and discharge. The following 3 patterns of changes were identified. In 41 patients, H-FABP levels (<4.3 ng/ml) at both admission and discharge were normal (Group 1). The remaining 72 patients had high initial H-FABP levels (≥4.3 ng/ml) at admission, and in 21 of them (29%), H-FABP decreased to the normal range at discharge (Group 2), whereas 51 had persistently high H-FABP levels despite improvement in symptoms and signs of CHF (Group 3). There were 33 cardiac events (29%) during the follow-up period, and Group 3 had significantly higher cardiac event rates than Groups 1 and 2 (p=0.0002). Group 3 had the highest cardiac risk among the groups (hazard ratio 5.68, p=0.012). Conclusion Serial measurement of the H-FABP level is a new monitoring tool that provides information to guide optimal therapy and management of CHF patients. (Circ J 2008; 72: 109 - 114)<br>

Journal

  • Circulation Journal

    Circulation Journal 72 (1), 109-114, 2008

    The Japanese Circulation Society

Citations (6)*help

See more

References(29)*help

See more

Details

Report a problem

Back to top